

Supplemental Table 1. Demographic and Pathologic Data for Patients with receipt of CPI: Placebo (n=9), TLPLDC (n=16), TLPLDC+G (n=18), and TLPO (n=35) arms.

Category		Treatment Arms								P-Value
		Placebo n=9		TLPLDC n=16		TLPLDC+G n=18		TLPO n=35		
		Count	Column %	Count	Column %	Count	Column %	Count	Column %	
Age (yrs)	Mean	63.2		68.3		69.2		68.2		0.684
Sex	Female	5	55.6%	6	37.5%	1	5.6%	14	40%	0.028
	Male	4	44.4%	10	62.5%	17	94.4%	21	60%	
Race	Asian	1	11.1%	0	0.0%	0	0.0%	0	0.0%	0.152
	Black	0	0.0%	0	0.0%	0	0.0%	0	0.0%	
	Hispanic	0	0.0%	0	0.0%	2	11.1%	0	0.0%	
	Native American	0	0.0%	0	0.0%	0	0.0%	0	0.0%	
	Other	0	0.0%	0	0.0%	0	0.0%	0	0.0%	
	White	8	88.9%	16	100%	16	88.9%	34	97.1%	
	White, Hispanic	0	0.0%	0	0.0%	0	0.0%	1	2.9%	
AJCC	III	6	66.7%	15	93.2%	8	44.4%	20	57.1%	0.02
	IV	3	33.3%	1	6.3%	16	55.6%	15	42.9%	
Staging	Missing	0	0.0%	0	0.0%	0	0.0%	1	2.9%	0.966
	Primary	2	22.2%	4	25.0%	4	22.2%	9	24.4%	
	Recurrent	7	77.8%	12	75.0%	14	77.89%	25	71.4%	

Supplemental Table 3. Demographic and Pathologic Data for Patients without receipt of CPI: Placebo (n=32), TLPLDC (n=31), TLPLDC+G (n=38), and TLPO (n=8) arms.

Category		Treatment Arms								P-Value
		Placebo n=32		TLPLDC n=31		TLPLDC+G n=38		TLPO n=8		
		Count	Column %	Count	Column %	Count	Column %	Count	Column %	
Age (yrs)	Mean	66.97		71.65		69.87		60.13		0.160
Sex	Female	9	28.1%	10	32.3%	15	39.5%	2	33%	0.728
	Male	23	71.9%	21	67.7%	23	60.5%	6	67%	
Race	Asian	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0.119
	Black	0	0.0%	0	0.0%	0	0.0%	1	12.5%	

	Hispanic	1	3.1%	1	3.2%	0	0.0%	0	0.0%	
	Native American	0	0.0%	0	0.0%	1	2.6%	0	0.0%	
	Other	0	0.0%	0	0.0%	1	2.6%	0	0.0%	
	White	31	96.9%	30	96.8%	36	94.7%	7	87.5%	
	White, Hispanic	0	0.0%	0	0.0%	0	0.0%	1	2.9%	
AJCC	III	27	84.4%	27	87.1%	32	84.2%	4	50.0%	0.158
	IV	5	15.6%	4	12.9%	6	15.8%	4	50.0%	
Staging	Missing	1	3.1%	0	0.0%	0	0.0%	0	0.0%	0.406
	Primary	15	46.9%	15	48.4%	17	44.7%	1	12.5%	
	Recurrent	16	50.0%	16	51.6%	21	55.3%	7	87.5%	

Supplemental Table 3: Types of CPI Administered by Treatment Arm (N=78)

	Ipilimumab	Pembrolizumab	Nivolumab	Number on active CPI during trial
Placebo N=9	7 (1 with nivo)	1	1	2
TLPLDC N=16	7 (1 with pembro, 1 with nivo)	3	6	1
TLPLDC+G N=18	12 (2 with pembro, 1 with nivo)	3	3	5
TLPO N=35	11 (3 with pembro, 7 with nivo)	4	20	5